Peritransplant and Long-Term Secretion of Interleukin-1β in Cyclosporine Treated Syngeneic Rats Allografted With Islets of Langerhans

Interleukin-1β (IL-1β) is one of the proinflammatory cytokines that may mediate primary nonfunction of islets of Langerhans, limiting the success of allogeneic transplantation. The aim of this study was to assess differences between the secretion of IL-1β as well as glycemia in peri- and long-term p...

Full description

Saved in:
Bibliographic Details
Published inTransplantation proceedings Vol. 37; no. 5; pp. 2375 - 2378
Main Authors Gürol, A.O., Kurşun, A.Ö., Süzergöz, F., Küçüksezer, U.C., Kıran, B., Kaya, S., Küçük, M., Deniz, G., Yılmaz, M.T.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.06.2005
Online AccessGet full text

Cover

Loading…
More Information
Summary:Interleukin-1β (IL-1β) is one of the proinflammatory cytokines that may mediate primary nonfunction of islets of Langerhans, limiting the success of allogeneic transplantation. The aim of this study was to assess differences between the secretion of IL-1β as well as glycemia in peri- and long-term periods of intraportal islet allo-transplantation with or without cyclosporine (CyA) immunosuppression. Inbred Wistar albino rats were transplanted intraportally with rat islets isolated by collagenase digestion. The two recipient groups (6 rats/group) were: group 1, control, islet transplantation (ITX) without any treatment and group 2, CyA-treated via the femoral muscle on days −1, 0, +1, and +2. Serum IL-1β (pg/mL) levels were measured by ELISA on days 0 (pre-ITX), +1, +2, and +195. Tail vein blood was used to evaluate glycemia (mg/dL). No major differences were observed in IL-1β secretion on days 0, +1, or +195 between the groups. Immunosuppressive treatment produced significantly lower secretion in group 2 ( P < .002) on day +2. Significantly greater secretions were detected at days +195, +1, and +195 compared to days 0, +2, and +2, respectively ( P < .002; P < .008; P < .002). Positive correlations were observed between IL-1β levels on days +1 and +2 ( r = 0.845, P < .034). The mean values in groups 1 and 2 on days 0, +1, and +2 were 140.6 ± 4.62 vs 119.1 ± 12.12, 73.1 ± 19.59 vs 88.3 ± 14.08, 106.5 ± 13.79 vs 92.5 ± 15.8, respectively. No animal in group 1 displayed glycemia while three group 2 animals did at day +195. However, a negative correlation was found between IL-1β on day 0 and glycemia on day +195 ( r = −0.999, P < .026). Our results suggest that IL-1β secretion, which is detrimental for islet engraftment, decreases at peritransplant day +2, but is upregulated during long-term graft survival both in controls and in CyA-treated recipients.
ISSN:0041-1345
1873-2623
DOI:10.1016/j.transproceed.2005.03.097